1. Is there a role for vindesine in the treatment of non-small cell lung cancer?

   • Jens Benn Sørensen
   • Heine H. Hansen

   Review Pages: 103 - 133

2. Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate

   • Richard L. Heideman
   • Cynthia McCully
   • David G. Poplack

   OriginalPaper Pages: 135 - 140

3. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography

   • Olaf van Tellingen
   • Agnes V. Kuijpers
   • Auke Bult

   OriginalPaper Pages: 141 - 150

4. VRCTC-310 — A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity

   • Robert A. Newman
   • Juan C. Vidal
   • Martin A. Etcheverry

   OriginalPaper Pages: 151 - 159

5. Chemotherapy of mammary carcinomas arising in ras transgenic mice

   • Daniel L. Dexter
   • Melody Diamond
   • Shih-Fong Chen

   OriginalPaper Pages: 161 - 168

6. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors

   • Douglas R. Adkins
   • Rebecca Irvin
   • C. F. LeMaistre

   OriginalPaper Pages: 169 - 179

7. Phase I trial of 5-fluorouracil by 24-hour infusion weekly

   • N. B. Haas
   • J. B. Hines
   • P. J. O'Dwyer

   OriginalPaper Pages: 181 - 185

8. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)

   • Susanne Danhauser-Riedl
   • Edith Hausmann
   • Axel-R. Hanauske

   OriginalPaper Pages: 187 - 195

9. Mitoxantrone (dihydroxyanthracenedione) in acute leukemia

   • John H. Saiki
   • W. J. Stuckey
   • Daniel D. Von Hoff

   OriginalPaper Pages: 197 - 200

10. 5-Azacytidine (NSC 102816) in refractory germ cell tumors

    • Bruce J. Roth
    • Paul Elson
    • Donald L. Trump

    Brief Report Pages: 201 - 202

11. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer

    • George Wilding
    • Gerald Grindey
    • Lawrence Einhorn

    OriginalPaper Pages: 203 - 205

12. Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma

    • M. Ernest Marshall
    • Michael K. Wolf
    • Mario Eisenberger

    OriginalPaper Pages: 207 - 209

13. Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma

    • Ronald M. Bukowski
    • James Young
    • James Finke

    OriginalPaper Pages: 211 - 217

14. Phase II trial of amonafide in advanced pancreas cancer

    • Cynthia Gail Leichman
    • Cathy Tangen
    • Thomas R. Fleming

    OriginalPaper Pages: 219 - 221

15. Evaluation of amonafide in disseminated malignant melanoma

    • Milan Slavik
    • Kenneth J. Kopecky
    • Michael K. Samson

    OriginalPaper Pages: 223 - 226

16. Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

    • Sarah A. Taylor
    • Jacqueline Benedetti
    • Alexander Hantel

    Brief Report Pages: 227 - 229

17. Phase II trial of carbetimer in metastatic melanoma

    • Walter D. Y. Quan Jr.
    • Malcolm S. Mitchell

    Brief Report Pages: 231 - 233

18. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma

    • J. A. Maroun
    • J. Skillings
    • E. Eisenhauer

    Brief Report Pages: 235 - 237

19. Announcement

    Announcement Pages: 239 - 239